Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

References 15

1. 1.
   Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 · 2021

   No notice
2. 2.

   Cui W, Yang K, Yang H. Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19. Front Mol Biosci. 2020;7:616341.

   Not in our library10.3389/fmolb.2020.616341

3. 3.
   Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease · 2020

   No notice
4. 4.
   Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease · 2020

   No notice
5. 5.

   Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY, et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem. 2020;63:12725-12747.

   Not in our library10.1021/acs.jmedchem.0c01063

6. 6.

   Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289-293.

   Not in our library10.1038/s41586-020-2223-y

7. 7.

   Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, Abeles SR, Torriani FJ. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med. 2021;384:1774-1775.

   Not in our library10.1056/nejmc2101927

8. 8.

   Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

   Not in our library10.1016/s0140-6736(20)30251-8

9. 9.

   Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov. 2013;12:595-610.

   Not in our library10.1038/nrd4050

10. 10.

    Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626-636.

    Not in our library10.1038/s41577-021-00592-1

11. 11.

    Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. 2021;49:36-40.

    Not in our library10.1016/j.coviro.2021.04.006

12. 12.
    Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design · 2016

    No notice
13. 13.
    Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases · 2005

    Corrected
14. 14.
    High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors · 2021

    No notice
15. 15.

    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.

    Not in our library10.1016/s0140-6736(20)30566-3

Cited by papers we hold 5

• Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines · 2025
  No notice
• SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376 · 2023
  No notice
• Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system · 2022
  No notice
• Structural biology of SARS-CoV-2: open the door for novel therapies · 2022
  No notice
• Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2 · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.